Welcome to our dedicated page for Ardent Health SEC filings (Ticker: ARDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ardent Health, Inc. (NYSE: ARDT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Ardent Health is a healthcare company in the medical care facilities industry that operates 30 acute care hospitals and approximately 280 sites of care across six states, and its filings offer detailed information on its financial condition, capital structure, governance and material events.
Among the key documents available are Current Reports on Form 8-K, where Ardent Health reports significant developments. Recent 8-K filings describe quarterly financial results, including the release of earnings for specific quarters and the use of non-GAAP measures such as Adjusted EBITDA and Adjusted EBITDAR. These filings often incorporate the related earnings press release as an exhibit, providing definitions of non-GAAP metrics, reconciliations to GAAP measures and discussions of operating metrics like admissions, surgeries and net patient service revenue per adjusted admission.
Other 8-K filings detail financing and capital structure actions. For example, Ardent Health has reported amendments to its Amended and Restated Term Loan Credit Agreement and its Amended and Restated ABL Credit Agreement, extending term loan maturities, adjusting interest rate spreads over Term SOFR and the base rate, and updating baskets for certain negative covenants. Another 8-K describes the authorization of a stock repurchase program of up to $50.0 million of the company’s common stock, including the potential use of open market purchases, privately negotiated transactions, block trades and Rule 10b5-1 plans.
Filings also cover governance and executive matters, such as leadership changes and the treatment of departures under the company’s Executive Severance Plan. References to proxy statements and severance plan documents in these filings point investors to additional information on executive compensation and severance arrangements.
On Stock Titan, these ARDT filings are updated as new documents are posted to EDGAR. AI-powered summaries help explain the substance of each filing, highlight key terms in credit agreements, clarify the implications of non-GAAP metrics and stock repurchase authorizations, and make it easier to understand how individual disclosures relate to Ardent Health’s hospital operations and financial profile.
Ardent Health, Inc. Chief Operating Officer Dave Caspers received an equity award of 35,673 shares of Common Stock on April 1, 2026 as a grant or award. The award represents restricted stock units that vest in three substantially equal installments on each anniversary of April 1, 2026, subject to his continued service with the company.
On the same date, 2,684 shares were withheld at $8.67 per share to cover tax obligations in accordance with Rule 16b-3, a routine tax-withholding disposition rather than an open-market sale. After these transactions, Caspers directly owned 35,604 shares of Common Stock.
Ardent Health EVP, GC and Secretary Stephen C. Petrovich received a grant of 24,904 shares of common stock as restricted stock units that vest in three substantially equal installments on each anniversary of April 1, 2026, subject to continued service. To cover tax obligations on RSU vesting, 1,425 shares on March 31, 2026 at $8.56 and 1,808 shares on April 1, 2026 at $8.67 were withheld rather than sold on the open market. Following these compensation-related transactions, he holds 774,707 shares directly, and 186,225 shares are reported as indirectly held in family GST‑2016 Exempt Family Trusts for which he disclaims beneficial ownership except for any pecuniary interest.
Ardent Health, Inc. senior vice president and chief accounting officer David Raynor reported routine equity compensation activity in the company’s stock. On April 1, 2026 he received a grant of 11,538 shares of common stock at no cost, tied to restricted stock units that vest in three substantially equal installments on each anniversary of April 1, 2026, subject to his continued service. To cover taxes owed on RSU vesting, 924 shares were withheld on April 1, 2026 at $8.67 per share and 819 shares were withheld on March 31, 2026 at $8.56 per share, consistent with Rule 16b-3 treatment rather than open‑market sales. Following these transactions, Raynor directly owned 130,445 shares of Ardent Health common stock.
Ardent Health, Inc. Chief Financial Officer Alfred Lumsdaine reported routine equity compensation activity in common stock. On April 1, 2026, he received a grant of 53,846 shares, representing restricted stock units that vest in three equal installments from April 1, 2026. To cover taxes on RSU vesting, the company withheld 2,510 shares on March 31, 2026 at $8.56 per share and 4,381 shares on April 1, 2026 at $8.67 per share under Rule 16b-3. Following these transactions, he directly holds 319,183 common shares.
Ardent Health, Inc. President and CEO Martin Bonick reported compensation-related stock activity involving restricted stock units and associated tax withholding.
On April 1, 2026, he received 134,615 shares of common stock as a grant or award. These restricted stock units vest in three substantially equal installments on each anniversary of April 1, 2026, subject to his continued service with the company.
To cover tax obligations upon vesting of restricted stock units under Rule 16b-3, 10,952 shares were withheld at a reference price of $8.67 per share on April 1, 2026 and 8,026 shares were withheld at $8.56 per share on March 31, 2026. Following these transactions, Bonick directly owned 1,437,937 shares of Ardent Health common stock.
Ardent Health, Inc. reported that Ethan Chernin, its President, Hospital Services, departed the company effective March 24, 2026. The company classified his departure as a “Qualifying Termination” under its Executive Severance Plan, meaning he will receive severance and related benefits subject to that plan’s terms.
Details of the severance framework are described in Ardent Health’s 2025 proxy statement and in the Executive Severance Plan previously filed as an exhibit to a Form 10-Q for the quarter ended June 30, 2024.
Ardent Health, Inc. is a Delaware-based holding company that operates a large, consumer-centric healthcare platform focused on mid-sized U.S. urban markets. As of December 31, 2025, it ran 30 acute care hospitals and 286 total sites of care with 4,281 licensed beds and more than 2,000 providers across Texas, Oklahoma, New Mexico, New Jersey, Idaho, and Kansas.
The company served about 1.2 million unique patients in 2025, totaling over 6.1 million visits, and reports leading inpatient market share positions in most of its eight regional systems. A differentiated joint venture model with academic medical centers, not-for-profit health systems, community physicians, and a foundation underpins 18 JV-operated hospitals, many structured as variable interest entities where Ardent holds majority economic interests and provides day-to-day management.
Ardent emphasizes quality and technology, citing 85% systemwide compliance with sepsis bundles, severe sepsis and septic shock mortality rates well below national averages, and strong Leapfrog safety results, including nine 2025 Top Hospital designations and 88% of graded hospitals earning A or B grades. A single Epic electronic health record instance and AI-enabled tools support value-based care initiatives, ambulatory expansion, and population health management.
Petrovich Stephen C. reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. executive vice president, general counsel and secretary Stephen C. Petrovich was granted 34,733 shares of common stock on March 11, 2026 as a performance-based award. The shares were earned under performance-vesting restricted stock units granted on July 18, 2024 and will vest on December 31, 2026, contingent on continued service.
Following this award, Petrovich directly owns 753,036 shares of Ardent Health common stock. The filing also reports additional indirect holdings of common stock through 2016 exempt family trusts benefiting his children, for which he disclaims beneficial ownership except for any pecuniary interest.
Ardent Health, Inc. Chief Financial Officer Alfred Lumsdaine reported an equity compensation award on Common Stock. He acquired 61,081 shares on March 11, 2026 at a stated price of $0.00 per share, reflecting a grant or award rather than an open-market purchase.
According to the footnote, these shares were earned based on 2024 and 2025 performance under performance-vesting restricted stock units granted on July 18, 2024, and will vest on December 31, 2026 if he remains in service through that date. Following this award, he directly holds 272,228 Common Stock shares.
Chernin Ethan reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. President of Health Services Ethan Chernin reported receiving a grant of 32,408 shares of Common Stock as compensation, with no purchase price paid per share.
These shares were earned based on 2024 and 2025 performance under performance-vesting restricted stock units awarded on July 18, 2024. They will vest on December 31, 2026, contingent on continued service through that date. After this award, Chernin directly holds 68,396 shares of Ardent Health common stock.